Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Smart Eye AB in conjunction with its listing on Nasdaq First North
Mandate

Vinge advises Smart Eye AB in conjunction with its listing on Nasdaq First North

November 11, 2016

Vinge has advised Smart Eye AB in connection with the listing of Smart Eye’s shares on Nasdaq First North.

In connection with the listing, a new issue of not more than 1 750 000 shares was performed whereupon Smart Eye will receive not more than SEK 80 500 000. The offer is directed to the general public and institutional investors. The prospectus was published on 10 November and the first day of trading is 7 December.

Vinge’s team primarily consisted of responsible partner Anders Strid, Magnus Pauli (client relationship), Frida Bäckegren (project manager due diligence and prospectus), Joel Zetterström and Natalie Bäck (IP), Jonas Lindeblad (employment), Björn Nicolai and Karin Wisenius (EU and competition), Victor Ericsson (tax) and company assistant Camilla Andersson.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025